替米沙坦联合舒洛地特治疗糖尿病肾病Ⅲ期临床观察

　　[摘要]目的 探究替米沙坦聯合舒洛地特治疗糖尿病肾病的临床效果。方法 选取2015年3月～2017年3月我院收治的64例糖尿病肾病Ⅲ期患者作为研究对象，采用随机数字表法将其分为对照组和研究组，每组各32例。两组患者均接受常规治疗，对照组患者在常规治疗的基础上加服替米沙坦，研究组患者在常规治疗的基础上联用替米沙坦和舒洛地特，两组患者均治疗8周。比较两组患者的治疗总有效率以及治疗前和治疗8周时的血清肌酐（Scr）、尿素氮（BUN）、尿蛋白排泄率（UAER）、超敏C-反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）含量。结果 研究组患者的治疗总有效率（93.75%）高于对照组（68.75%），差异有统计学意义（P<0.05）。治疗前，两组患者的Scr、BUN、UAER比较，差异无统计学意义（P>0.05）。治疗后，两组患者的UAER明显低于治疗前，研究组患者的UAER明显低于对照组，差异均有统计学意义（P<0.05）。治疗前，两组患者的hs-CRP、TNF-α含量比较，差异无统计学意义（P>0.05）。治疗后，两组患者的hs-CRP、TNF-α含量均明显低于治疗前，研究组患者的hs-CRP、TNF-α含量均明显低于对照组，差异有统计学意义（P<0.05）。结论 替米沙坦联合舒洛地特治疗糖尿病肾病临床效果显著，明显优于单用替米沙坦，建议临床上推广应用。
　　[关键词]替米沙坦；舒洛地特；糖尿病肾病；临床观察
　　[中图分类号] R654.2 [文献标识码] A [文章编号] 1674-4721（2018）2（b）-0126-03
　　Clinical observation of Telmisartan combined with Sulodexide for diabetic kidney disease at stage Ⅲ
　　FANG Hai-ming
　　Department of Nephrology，Kangmei Hospital in Puning City，Guangdong Province，Puning 515300，China
　　[Abstract]Objective To investigate the clinical efficacy of Telmisartan combined with Sulodexide in the treatment of diabetic nephropathy.Methods 64 patients with diabetic kidney disease at stage Ⅲ treated in our hospital from March 2015 to March 2017 were selected as subjects of this study.They were divided into control group and study group with random number table method，32 cases in each group.Two groups of patients were treated with conventional therapy，the patients of control group were given Telmisartan on the addition of conventional treatment，the patients of study group were given Telmisartan and Sulodexide on the basis of conventional treatment，all patients were treated for 8 weeks.The total effective rate of treatment，the serum creatinine （Scr），urea nitrogen （BUN），microprojection rate （UAER），high sensitivity C-reactive protein （hs-CRP） and tumor necrosis factor-α （TNF-α） before and after 8 weeks of treatmen were comapred between two groups.Results The total effective rate in the study group （93.75%） was higher than that in the control group （68.75%），and the difference was statistically significant （P<0.05）.There was no significant difference in the Scr，BUN and UAER between the two groups before treatment （P>0.05）.After treatment，the UAER in both groups were lower than before treament，the UAER in the study group was significantly lower than that in the control group，and the difference was statistically significant （P<0.05）.Before treatment，there was no statistically significant difference in hs-CRP and TNF-α in the two groups （P>0.05）.After treatment，the levels of hs-CRP and TNF-α in both groups were significantly lower than before treatment，and the levels of hs-CRP and TNF-α in the study group were significantly lower than those in the control group，and the differences were statistically significant （P<0.05）.Conclusion The efficacy of Telmisartan combined with Sulodexide in the treatment of diabetic kidney disease is significantly better than that of telmisartan alone，and it is recommended to be widely used clinically.

相关热词搜索：观察 治疗 联合 期临床 糖尿病肾病